Dactinomycin
drugOn this page
Also known as Actinomycin c1Actinomycin dActinomycin i1Actinomycin ivActinomycin x1Actinomycin-dCosmegenCosmegen lyovacDactinomicinaDactinomycineDactinomycinumDilactone actinomycin d acidGNF-PF-2290GNF-Pf-1977MeractinomycinNCI-C04682NSC-3053Oncostatin kActinomycin D analogue
Summary
Dactinomycin (CHEMBL1554) is an approved protein (ATC L01DA01); indicated across 20 conditions including neoplasm and wilms tumor.
At a glance
- Status: Approved (max clinical phase 4)
- Modality: Protein
- ATC class: L01DA01
- Indications: 20 conditions
- Clinical trials: 56
- Chemistry: 1255.4 Da · C62H86N12O16
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL1554 |
| Name | Dactinomycin |
| Type | Protein |
| Max phase | 4 |
| FDA approved | yes |
| PubChem CID | 457193 |
| ChEBI | CHEBI:27666 |
| ATC | L01DA01 |
| Molecular formula | C62H86N12O16 |
| Molecular weight | 1255.4 |
| InChIKey | RJURFGZVJUQBHK-IIXSONLDSA-N |
SMILES: C[C@@H]1[C@@H](C(=O)N[C@@H](C(=O)N2CCC[C@H]2C(=O)N(CC(=O)N([C@H](C(=O)O1)C(C)C)C)C)C(C)C)NC(=O)C3=C4C(=C(C=C3)C)OC5=C(C(=O)C(=C(C5=N4)C(=O)N[C@H]6[C@H](OC(=O)[C@@H](N(C(=O)CN(C(=O)[C@@H]7CCCN7C(=O)[C@H](NC6=O)C(C)C)C)C)C(C)C)C)N)C
IUPAC name: 2-amino-4,6-dimethyl-3-oxo-1-N,9-N-bis[(3R,6S,7R,10S,16S)-7,11,14-trimethyl-2,5,9,12,15-pentaoxo-3,10-di(propan-2-yl)-8-oxa-1,4,11,14-tetrazabicyclo[14.3.0]nonadecan-6-yl]phenoxazine-1,9-dicarboxamide
Also known as: Actinomycin c1, Actinomycin d, Actinomycin i1, Actinomycin iv, Actinomycin x1, Actinomycin-d, Cosmegen, Cosmegen lyovac, Dactinomicina, Dactinomycin, Dactinomycine, Dactinomycinum
Patent coverage: 45,027 distinct patent families (175,245 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.
Targets
Targets
Broader ChEMBL bioactivity targets: 23 (assay-derived). Sample: Microtubule-associated protein tau, Nuclear receptor ROR-gamma, Survival motor neuron protein, Fructose-bisphosphate aldolase, ATP-dependent DNA helicase Q1, RecQ-like DNA helicase BLM, Ferritin light chain, Histone-lysine N-methyltransferase 2A, Prostaglandin G/H synthase 1, Polyunsaturated fatty acid lipoxygenase ALOX15.
Bioactivity
ChEMBL activities: 15 potent at pChembl ≥ 5 of 35 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):
| Target | pChembl | Type | Value | Unit | Activity ID |
|---|---|---|---|---|---|
| P51450 | 7.75 | Potency | 17.8 | nM | CHEMBL_ACT_4778592 |
| P51450 | 7.65 | Potency | 22.4 | nM | CHEMBL_ACT_4988125 |
| HTT | 7.5 | Potency | 31.6 | nM | CHEMBL_ACT_3751964 |
| P51450 | 7.5 | Potency | 31.6 | nM | CHEMBL_ACT_4987316 |
| P51450 | 7.05 | Potency | 89.1 | nM | CHEMBL_ACT_4113719 |
| HIF1A | 6.6 | Potency | 251.2 | nM | CHEMBL_ACT_3769507 |
| SMN1 | 6.5 | Potency | 316.2 | nM | CHEMBL_ACT_3879892 |
| RECQL | 5.85 | Potency | 1412 | nM | CHEMBL_ACT_5056092 |
| RECQL | 5.45 | Potency | 3548 | nM | CHEMBL_ACT_3673741 |
| P25779 | 5.4 | Potency | 3981 | nM | CHEMBL_ACT_3977234 |
| Q60631 | 5.3 | IC50 | 5000 | nM | CHEMBL_ACT_1007095 |
| GRB2 | 5.3 | IC50 | 5000 | nM | CHEMBL_ACT_261295 |
| A8B2U2 | 5.15 | Potency | 7063 | nM | CHEMBL_ACT_4605320 |
| BLM | 5.15 | Potency | 7080 | nM | CHEMBL_ACT_4885952 |
| DDR2 | 5.05 | IC50 | 9000 | nM | CHEMBL_ACT_15240097 |
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
20 indications (2 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| neoplasm | 4 | MONDO:0005070 | EFO:0000616 |
| Wilms tumor | 4 | MONDO:0006058 | MONDO:0019004 |
| Ewing sarcoma | 3 | MONDO:0012817 | EFO:0000174 |
| alveolar rhabdomyosarcoma | 3 | MONDO:0009994 | EFO:0000248 |
| embryonal rhabdomyosarcoma | 3 | MONDO:0009993 | EFO:0000437 |
| leukemia | 3 | MONDO:0005059 | EFO:0000565 |
| lymphoma | 3 | MONDO:0005062 | EFO:0000574 |
| sarcoma | 3 | MONDO:0005089 | EFO:0000691 |
| rhabdomyosarcoma | 3 | MONDO:0005212 | EFO:0002918 |
| choriocarcinoma | 3 | MONDO:0005207 | EFO:0002893 |
| hydatidiform mole | 3 | MONDO:0006248 | EFO:1000298 |
| brain cancer | 3 | MONDO:0001657 | MONDO:0001657 |
| kidney cancer | 3 | MONDO:0002367 | MONDO:0002367 |
| soft tissue sarcoma | 3 | MONDO:0018078 | EFO:1001968 |
| melanoma | 2 | MONDO:0005105 | EFO:0000756 |
| central nervous system neoplasm | 2 | MONDO:0006130 | EFO:1000158 |
| testicular cancer | 2 | MONDO:0005447 | EFO:0004281 |
3 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.
Clinical trials
Total trials: 56.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE3 | 29 |
| PHASE2 | 19 |
| Not specified | 4 |
| PHASE1/PHASE2 | 2 |
| PHASE4 | 1 |
| PHASE1 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT00491946 | PHASE4 | UNKNOWN | A Pharmacokinetic Study of Actinomycin-D and Vincristine in Children With Cancer |
| NCT00352534 | PHASE3 | ACTIVE_NOT_RECRUITING | Vincristine, Dactinomycin, and Doxorubicin With or Without Radiation Therapy or Observation Only in Treating Younger Patients Who Are Undergoing Surgery for Newly Diagnosed Stage I, Stage II, or Stage III Wilms’ Tumor |
| NCT00379340 | PHASE3 | ACTIVE_NOT_RECRUITING | Combination Chemotherapy With or Without Radiation Therapy in Treating Young Patients With Newly Diagnosed Stage III or Stage IV Wilms’ Tumor |
| NCT00945009 | PHASE3 | ACTIVE_NOT_RECRUITING | Combination Chemotherapy and Surgery in Treating Young Patients With Wilms Tumor |
| NCT02567435 | PHASE3 | ACTIVE_NOT_RECRUITING | Combination Chemotherapy With or Without Temsirolimus in Treating Patients With Intermediate Risk Rhabdomyosarcoma |
| NCT03669783 | PHASE3 | RECRUITING | Clinical Trial for Patients With a Stage IV Childhood Renal Tumor, Comparing Upfront Vincristine, Actinomycin-D and Doxorubicin (Standard Arm) With Upfront Vincristine, Carboplatin and Etoposide (Experimental Arm) |
| NCT04994132 | PHASE3 | ACTIVE_NOT_RECRUITING | A Study to Compare Early Use of Vinorelbine and Maintenance Therapy for Patients With High Risk Rhabdomyosarcoma |
| NCT05304585 | PHASE3 | RECRUITING | Chemotherapy for the Treatment of Patients With Newly Diagnosed Very Low-Risk and Low Risk Fusion Negative Rhabdomyosarcoma |
| NCT06401330 | PHASE3 | RECRUITING | A Study Using Risk Factors to Determine Treatment for Children With Favorable Histology Wilms Tumors (FHWT) |
| NCT06647953 | PHASE3 | RECRUITING | Testing a Standardized Approach to Surgery and Chemotherapy for Type I Pleuropulmonary Blastoma or the Addition of an Anti-cancer Drug, Topotecan, to the Usual Treatment for Types II and III Pleuropulmonary Blastoma |
| NCT07466316 | PHASE3 | NOT_YET_RECRUITING | A Study Comparing Higher Dose Chemotherapy Over a Shorter Amount of Time to Lower Dose Chemotherapy Plus Maintenance Over a Longer Amount of Time in Patients With Newly Diagnosed Intermediate-Risk Rhabdomyosarcoma (IR RMS) |
| NCT00002516 | PHASE3 | UNKNOWN | Combination Chemotherapy Plus Surgery and Radiation Therapy in Treating Patients With Ewing’s Sarcoma |
| NCT00002610 | PHASE3 | COMPLETED | Chemotherapy With or Without Surgery, Radiation Therapy, or Stem Cell Transplantation in Treating Young Patients With Kidney Tumors |
| NCT00002611 | PHASE3 | COMPLETED | Combination Chemotherapy Alone or With Radiation Therapy in Treating Children With Kidney Cancer |
| NCT00002766 | PHASE3 | COMPLETED | Comparison of Two Combination Chemotherapy Regimens in Treating Adults With Previously Untreated Leukemia or Lymphoma |
| NCT00002898 | PHASE3 | COMPLETED | Surgery Followed by Chemotherapy in Treating Young Patients With Soft Tissue Sarcoma |
| NCT00002995 | PHASE3 | COMPLETED | Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Newly Diagnosed Rhabdomyosarcoma |
| NCT00003702 | PHASE3 | COMPLETED | Methotrexate Compared With Dactinomycin in Treating Patients With Gestational Trophoblastic Neoplasia |
| NCT00003804 | PHASE3 | UNKNOWN | Chemotherapy Plus Surgery in Treating Children at Risk of or With Stage I Wilms’ Tumor |
| NCT00003958 | PHASE3 | COMPLETED | Combination Chemotherapy in Treating Patients With Previously Untreated Rhabdomyosarcoma |
| NCT00020566 | PHASE3 | UNKNOWN | Combination Chemotherapy With or Without Peripheral Stem Cell Transplantation, Radiation Therapy, and/or Surgery in Treating Patients With Ewing’s Sarcoma |
| NCT00047138 | PHASE3 | UNKNOWN | Chemotherapy Before and After Surgery in Treating Children With Wilm’s Tumor |
| NCT00075582 | PHASE3 | COMPLETED | Vincristine, Dactinomycin, and Cyclophosphamide With or Without Radiation Therapy in Treating Patients With Newly Diagnosed Low-Risk Rhabdomyosarcoma |
| NCT00162695 | PHASE3 | TERMINATED | Rhabdomyosarcoma and Malignant Soft Tissue Tumours of Childhood |
| NCT00354744 | PHASE3 | COMPLETED | High-Dose Combination Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Metastatic Rhabdomyosarcoma or Ectomesenchymoma |
| NCT00354835 | PHASE3 | COMPLETED | Combination Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Rhabdomyosarcoma |
| NCT00379457 | PHASE3 | UNKNOWN | Combination Chemotherapy in Treating Young Patients With Nonmetastatic Rhabdomyosarcoma |
| NCT01014767 | PHASE3 | TERMINATED | Intercontinental Multidisciplinary Registry and Treatment Optimization Study for Choroid Plexus Tumors |
| NCT01535053 | PHASE3 | COMPLETED | Dactinomycin or Methotrexate in Treating Patients With Low-Risk Gestational Trophoblastic Neoplasia |
| NCT02639650 | PHASE3 | UNKNOWN | Study of Paclitaxel Plus Cisplatin as the First-line Chemotherapy in High Risk Gestational Trophoblastic Tumor |
| NCT01871766 | PHASE2 | ACTIVE_NOT_RECRUITING | Risk-Adapted Focal Proton Beam Radiation and/or Surgery in Patients With Low, Intermediate and High Risk Rhabdomyosarcoma Receiving Standard or Intensified Chemotherapy |
| NCT04332874 | PHASE2 | RECRUITING | A Study of Pembrolizumab Plus Local Chemotherapy Using Isolated Limb Infusion (ILI) for Patients With Sarcoma in the Arm or Leg |
| NCT04388839 | PHASE2 | ACTIVE_NOT_RECRUITING | Evolutionary Therapy for Rhabdomyosarcoma |
| NCT04625907 | PHASE1/PHASE2 | RECRUITING | FaR-RMS: An Overarching Study for Children and Adults With Frontline and Relapsed RhabdoMyoSarcoma |
| NCT06020755 | PHASE2 | RECRUITING | Toripalimab Plus Actinomycin-D As Fist-Line Treatment for GTN with FIGO Score 7 |
| NCT06023641 | PHASE2 | RECRUITING | Treatment of Newly Diagnosed Rhabdomyosarcoma Using Molecular Risk Stratification and Liposomal Irinotecan Based Therapy in Children With Intermediate and High Risk Disease |
| NCT00002489 | PHASE2 | COMPLETED | Combination Chemotherapy in Treating Children With Non-testicular Malignant Germ Cell Tumors |
| NCT00003688 | PHASE2 | COMPLETED | Dactinomycin in Treating Patients With Persistent or Recurrent Gestational Trophoblastic Neoplasia |
| NCT00003955 | PHASE2 | COMPLETED | Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Metastatic Rhabdomyosarcoma or Sarcoma |
| NCT00004250 | PHASE2 | COMPLETED | Isolated Limb Infusion of Chemotherapy in Treating Patients With Melanoma or Soft Tissue Sarcoma of the Arm or Leg That Cannot Be Removed By Surgery |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).